TrialJAMA oncology2024

Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses From the KEYNOTE-826 Randomized Clinical Trial.

Krishnansu S Tewari et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.